Арилжаа HOOKIPA Pharma Inc. - HOOK CFD

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company''s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.